As of 2026-09-26, the EV/EBITDA ratio of EyePoint Pharmaceuticals Inc (EYPT) is -0.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EYPT's latest enterprise value is 268.84 mil USD. EYPT's TTM EBITDA according to its financial statements is -314.38 mil USD. Dividing these 2 quantities gives us the above EYPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 12.8x | 8.4x |
| Forward P/E multiples | 11.2x - 16.0x | 14.1x |
| Fair Price | (32.94) - (37.78) | (32.90) |
| Upside | -1002.5% - -1135.1% | -1001.2% |
| Date | EV/EBITDA |
| 2026-09-24 | -0.86 |
| 2026-09-23 | -0.88 |
| 2026-09-22 | -0.99 |
| 2026-09-21 | -0.98 |
| 2026-09-18 | -0.92 |
| 2026-09-17 | -0.97 |
| 2026-09-16 | -0.79 |
| 2026-09-15 | -0.86 |
| 2026-09-14 | -1.05 |
| 2026-09-11 | -1.05 |
| 2026-09-10 | -1.05 |
| 2026-09-09 | -1.08 |
| 2026-09-08 | -1.16 |
| 2026-09-04 | -1.16 |
| 2026-09-03 | -1.16 |
| 2026-09-02 | -1.23 |
| 2026-09-01 | -1.16 |
| 2026-08-31 | -1.14 |
| 2026-08-28 | -1.13 |
| 2026-08-27 | -1.18 |
| 2026-08-26 | -1.30 |
| 2026-08-25 | -1.30 |
| 2026-08-24 | -1.26 |
| 2026-08-21 | -1.41 |
| 2026-08-20 | -1.43 |
| 2026-08-19 | -1.73 |
| 2026-08-18 | -1.46 |
| 2026-08-17 | -1.26 |
| 2026-08-14 | -4.52 |
| 2026-08-13 | -4.10 |
| 2026-08-12 | -4.12 |
| 2026-08-11 | -3.96 |
| 2026-08-10 | -3.97 |
| 2026-08-07 | -4.24 |
| 2026-08-06 | -3.89 |
| 2026-08-05 | -3.70 |
| 2026-08-04 | -3.51 |
| 2026-08-03 | -3.75 |
| 2026-07-31 | -3.70 |
| 2026-07-30 | -3.90 |
| 2026-07-29 | -3.59 |
| 2026-07-28 | -3.60 |
| 2026-07-27 | -3.75 |
| 2026-07-24 | -3.68 |
| 2026-07-23 | -3.77 |
| 2026-07-22 | -3.83 |
| 2026-07-21 | -3.96 |
| 2026-07-20 | -3.83 |
| 2026-07-17 | -4.04 |
| 2026-07-16 | -3.96 |